VA
CORT icon

Vident Advisory’s Corcept Therapeutics CORT Stock Holding History

Vident Advisory’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$504K Sell
12,502
-2,309
-16% -$86.3K ﹤0.01% 1254
2025
Q4 		$515K Sell
14,811
-2,114
-12% -$166K ﹤0.01% 1151
2025
Q3 		$1.41M Sell
16,925
-2,971
-15% -$215K 0.01% 684
2025
Q2 		$1.46M Sell
19,896
-44,698
-69% -$3.24M 0.02% 611
2025
Q1 		$7.38M Sell
64,594
-45,184
-41% -$2.75M 0.11% 177
2024
Q4 		$5.53M Sell
109,778
-6,114
-5% -$320K 0.1% 194
2024
Q3 		$5.36M Sell
115,892
-70,128
-38% -$2.49M 0.14% 146
2024
Q2 		$6.04M Buy
186,020
+3,601
+2% +$98.6K 0.17% 120
2024
Q1 		$4.6M Buy
182,419
+94,266
+107% +$2.23M 0.1% 221
2023
Q4 		$2.86M Sell
88,153
-40
-0% -$1.1K 0.07% 296
2023
Q3 		$2.4M Buy
+88,193
New +$2.55M 0.07% 279

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Vident Advisory's CORT Position: Q1 2026 in Review

Vident Advisory reduced its Corcept Therapeutics (CORT) stake by 16% in Q1 2026, selling an estimated $86.3K and leaving 12,502 shares worth $504K. The position accounts for ﹤0.01% of the portfolio, ranked #1254.

Vident Advisory first reported a position in CORT in Q3 2023 and has held it in 11 quarters since. The position peaked at $7.38M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Vident Advisory held 12,502 shares of Corcept Therapeutics worth $504K as of Q1 2026.
  • Vident Advisory sold 2,309 Corcept Therapeutics shares in Q1 2026, an estimated $86.3K.
  • Corcept Therapeutics made up ﹤0.01% of Vident Advisory's portfolio in Q1 2026, its #1254 holding.
  • Vident Advisory first reported a position in Corcept Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Vident Advisory's Corcept Therapeutics position peaked at $7.38M in Q1 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.